Clover Health (CLOV) Gains 9% After-Hours as Managed Care Names Rally

As seen on the 24/7 Wall St. homepage on November 6, 2026.

CLOV Clover Health
After-hours
$4.82
+9.05% off the open $4.42
$4.9$4.8$4.7

The 9.05% run came the same day Humana, a competitor, posted Q3 2026 results. Managed care names moved together into the close.

Before the move last 24 hours
  1. Earnings release
    Related company: HUM, competitor

    Humana Q3 2026 earnings release

    SEC EDGAR
Related stocks today
  • HUMHumanaCompetitor+4.6%
    Dec 31, 2025 · SEC 10-K
  • CVSCVS HealthCompetitor+3.8%
    Feb 27, 8:08 AM ET · SEC 10-K
  • ELVElevance HealthCompetitor+0.8%
    Dec 31, 2025 · SEC 10-K

Moves: Nov 6, 4:20 PM ET · Alpha Vantage quote

3 more related stocks · 4 have no US listing

Continue ReadingShow less

Clover Health shares climbed roughly 9% to $4.82 in after-hours trading, putting the stock among the stronger performers in managed care on the day.

The catalyst in the sector was Humana's Q3 2026 earnings release, which landed during the regular session. Managed care names broadly moved together into the close, suggesting investors read the Humana report as a positive signal for the sector rather than a company-specific story.

Sponsored

Humana gained 4.61% on the day, and Clover Health's after-hours move outpaced Humana, CVS Health and Elevance Health, a sign the stock drew amplified attention relative to its larger peers.

After-hours moves are magnified by thinner volume and often fade when regular trading resumes, so the open of the next session will show whether this level holds.

Sources

Mentioned: CLOV, HUM, CVS, ELV

Related Market Updates

HUM Humana
Q3 2026
EPS
-$0.70
est -$1.00 +30.3%
Revenue
$41.16B
est $40.89B +0.7%

Humana raised its full-year adjusted EPS floor to at least $9.50 from at least $9.00 after a smaller quarterly loss than Wall Street expected, with the Insurance benefit ratio landing at 93.7% versus management's own guidance of slightly above 94%. That is a rare upward revision in a group where peers keep flagging rising medical costs.

Read more
CAH Cardinal Health
Q1 2027
EPS
$3.26
est $2.94 +10.9%
Revenue
$67.51B
est $66.51B +1.5%

Full-year guidance went up to $12.80 to $13.00 per share, and management locked in a binding letter of intent to renew its CVS Health distribution agreements, removing the biggest customer-concentration question hanging over the stock. Pharmaceutical and Specialty Solutions profit rose 17%, the fourth straight quarter of beating EPS expectations.

Read more
Earnings · 2026 Q3 Andrew Toy Chief Executive Officer, Clover Health
Through Clover Assistant, we are committed to delivering better clinical quality and lower total cost of care. We are pleased that this continues to show up in our results, with ~98% of our members enrolled in our 5 Star rated PPO for Payment Year 2028, alongside our third consecutive year of nation-leading HEDIS performance.

Star ratings are where Medicare Advantage bonus money is won or lost, and while CVS and Aetna fight CMS in court over their downgrades, Clover's CEO says nearly all of its membership sits in a 5-Star plan for Payment Year 2028. That locks in bonus payments at a $2 billion company whose rivals are litigating to protect theirs.

Read more
CLOV Clover Health
Q3 2026
EPS
$0.01
est $0.01 +0.0%
Revenue
$759M
est $738M +2.8%

Clover Health is now running a real profit engine, turning a year-ago loss into GAAP net income of $6.4 million. Management raised the low end of every full-year 2026 target and says 2027 open enrollment is tracking well.

Read more
CVS CVS Health
Regular session
$80.68
-5.14% open $85.05
$83$81$78

The 5.14% slide to $80.68 comes on the same day the company reported a Q3 2026 earnings beat, with investors focused past the headline numbers. Roughly $5 billion of a $103 billion market cap gone in one session.

Read more
UNH UnitedHealth Group
Regular session
$411.60
+4.20% open $395.00
$415$404$394

A 4.2% move to $411.60 adds roughly $15 billion to the largest managed-care insurer, and it comes after CVS, a competitor, reported a Q3 earnings beat this morning. Sector sentiment is getting repriced.

Read more
CVS CVS Health
Regular session
$80.96
-4.81% open $85.05
$83$81$78

Roughly $5 billion of CVS Health's value came off in one session, a 4.8% slide to $80.96, even though it reported a Q3 earnings beat the same day. Guidance and margin commentary are what to check next.

Read more
Exec Sum @exec_sum

A breakup would hand shareholders separate stakes in the retail pharmacy and insurance/PBM businesses, the unit already in the FTC's crosshairs. Holders should keep an eye on the stock for confirmation from the company.

BREAKING: $CVS plans to split into two companies, in one of the biggest spinoffs in healthcare history
  • Replies1
  • Reposts0
  • Likes0
Read more
CVS CVS Health
Q3 2026
EPS
$2.09
est $1.65 +26.6%
Revenue
$108.40B
est $104.69B +3.5%

Aetna is the story: the medical benefit ratio improved to 91.3% from 92.8%, a managed-care cost trend moving the right way. Management raised full-year adjusted EPS guidance to at least $8.20 from $7.90 to $8.10.

Read more
Insider sale Mark Kaye
Sold Elevance Health, Inc. $1M2,343 shares @ $441.34

Elevance's CFO cut roughly a third of his reported common stock in one day, selling 10,584 shares for about $4.65 million into prices as high as $447.19. No 10b5-1 plan is flagged, which makes this a discretionary exit by the person who knows the Medicare Advantage cost math best.

Read more
ELV Elevance Health
Regular session
$426.70
-4.38% open $446.25

The managed-care insurer heads into today's earnings report already on the back foot, down 4.38% on the day. That slide sets a low bar for how the report lands.

Read more